MIMEDX Announces Launch of EPIXPRESS®
MiMedx (Nasdaq: MDXG) announced on October 6, 2025 the launch of EPIXPRESS, a next‑generation lyophilized human placental allograft added to its Advanced Wound Care portfolio.
EPIXPRESS is a PURION®‑processed, thick tri‑layer product that adds fenestrations to improve fluid movement versus EPIEFFECT and is intended for acute and chronic hard‑to‑heal wounds including diabetic foot ulcers (DFUs), venous leg ulcers (VLUs), deep or tunneling wounds, and wounds requiring suture fixation.
The company characterized the product as an organically developed, market‑driven innovation designed to expand clinician treatment options.
MiMedx (Nasdaq: MDXG) ha annunciato il 6 ottobre 2025 il lancio di EPIXPRESS, un allograft placentare umano liofilizzato di nuova generazione aggiunto al suo portafoglio Advanced Wound Care.
EPIXPRESS è un prodotto spesso a tre strati processato con PURION® che aggiunge fenestrazioni per migliorare il movimento dei fluidi rispetto a EPIEFFECT ed è destinato a ferite acute e croniche difficili da guarire, tra cui ulcere del piede diabetico (DFU), ulcere venose degli arti inferiori (VLU), ferite profonde o con tunnel e ferite che richiedono fissazione suturale.
L'azienda ha descritto il prodotto come un'innovazione sviluppata organicamente, guidata dal mercato, progettata per ampliare le opzioni di trattamento clinico.
MiMedx (Nasdaq: MDXG) anunció el 6 de octubre de 2025 el lanzamiento de EPIXPRESS, un aloinjerto placentario humano liofilizado de última generación añadido a su cartera de Advanced Wound Care.
EPIXPRESS es un producto grueso de tres capas procesado con PURION® que añade fenestraciones para mejorar el movimiento de fluidos en comparación con EPIEFFECT y está destinado a heridas agudas y crónicas de difícil curación, incluidas úlceras del pie diabético (DFU), úlceras venosas de piernas (VLU), heridas profundas o con túneles, y heridas que requieren fijación con sutura.
La empresa lo describió como una innovación desarrollada de forma orgánica y orientada al mercado, diseñada para ampliar las opciones de tratamiento para los clínicos.
MiMedx (Nasdaq: MDXG)는 2025년 10월 6일에 고세대의 동결 건조 인간 태반 동종이식물인 EPIXPRESS를 Advanced Wound Care 포트폴리오에 추가한다고 발표했다.
EPIXPRESS는 PURION® 가공된 두꺼운 삼중층 제품으로, EPIEFFECT에 비해 체액의 흐름을 개선하기 위해 개구를 추가하며, 당뇨발 궤양(DFU), 다리 정맥 궤양(VLU), 심부 또는 터널형 상처, 봉합 고정이 필요한 상처를 포함한 급성 및 만성 난치성 상처를 대상으로 한다.
회사는 이 제품을 시장 주도형 혁신으로 organically 개발된 것으로 설명하며 임상의 치료 옵션을 확대하기 위한 목적이라고 밝혔다.
MiMedx (Nasdaq: MDXG) a annoncé le 6 octobre 2025 le lancement de EPIXPRESS, une allogreffe placentale humaine lyophilisée de nouvelle génération ajoutée au portefeuille Advanced Wound Care.
EPIXPRESS est un produit épais à trois couches traité par PURION® qui ajoute des fenestrations pour améliorer la circulation des fluides par rapport à EPIEFFECT et est destiné aux plaies aiguës et chroniques difficiles à guérir, notamment ulcères du pied diabétique (DFU), ulcères veineux des jambes (VLU), plaies profondes ou tunnellées et plaies nécessitant une fixation par suture.
L’entreprise a décrit le produit comme une innovation développée organiquement, guidée par le marché, conçue pour élargir les options de traitement des cliniciens.
MiMedx (Nasdaq: MDXG) kündigte am 6. Oktober 2025 die Einführung von EPIXPRESS an, eine nächste Generation lyophilisierte menschliche Plazenta-Allograft, die dem Portfolio der Advanced Wound Care hinzugefügt wird.
EPIXPRESS ist ein PURION®-verarbeitetes, dickes Dreischichtprodukt, das Fenestrationen hinzufügt, um den Flüssigkeitsfluss im Vergleich zu EPIEFFECT zu verbessern, und richtet sich an akute und chronische schwer heilende Wunden, einschließlich diabetischer Fußgeschwüre (DFU), venöser Beingegeschwüre (VLU), tiefe oder tunnellierte Wunden und Wunden, die eine Nähte-Fixierung erfordern.
Das Unternehmen beschrieb das Produkt als organisch entwickeltes, marktorientiertes Innovationsprojekt, das darauf abzielt, die Behandlungsmöglichkeiten für Kliniker zu erweitern.
MiMedx (Nasdaq: MDXG) أعلن في 6 أكتوبر 2025 عن إطلاق EPIXPRESS، وهو طُعْمٌ مَشَبَّك ثلاثي الطبقات من المشيمة البشرية المجففة بالتجميد، أُضيف إلى محفظة Advanced Wound Care.
يُعَدّ EPIXPRESS منتجاً سميكاً ثلاثي الطبقات مُعَالَجاً بـ PURION®، ويضيف فتحات (fenestrations) لتحسين حركة السوائل مقارنةً بـ EPIEFFECT، وهو مخصص للجروح الحادّة والمزمنة صعبة الشفاء بما في ذلك قرحات القدم السكري (DFU)، قرحات الساق الوريدية (VLU)، الجروح العميقة أو التي لها قنوات، والجروح التي تتطلب تثبيتاً بخيط جراحي.
وصفته الشركة بأنه ابتكار مُطوّر بشكل عضوي، مدفوع بسوقه، يهدف إلى توسيع خيارات علاج المتخصصين.
MiMedx (Nasdaq: MDXG) 于 2025年10月6日 宣布推出 EPIXPRESS，这是纳入其高级创面护理组合的新一代冻干人胎盘同种异体移植物。
EPIXPRESS 是经 PURION® 处理的厚三层产品，增设孔隙以改善液体流动，与 EPIEFFECT 相比更利于液体流动，适用于急性和难愈合的慢性创面，包括 糖尿病足溃疡（DFU）、腿部静脉溃疡（VLU）、深部或有隧道的创面以及需要缝合固定的创面。
公司将该产品描述为一种有机开发、以市场为驱动的创新，旨在扩大临床医生的治疗选择。
- None.
- None.
Next-Generation, Lyophilized Human Placental Allograft Further Expands Company’s Broad Portfolio of Advanced Wound Care (“AWC”) Products
MARIETTA, Ga., Oct. 06, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the launch of EPIXPRESS®, the Company’s newest addition to its portfolio of AWC solutions.
“I am pleased to announce our latest, organically developed addition to our product portfolio today with the launch of EPIXPRESS,” said Joseph H. Capper, MIMEDX Chief Executive Officer. “With EPIXPRESS, our R&D team has built upon the fantastic attributes the market loves about EPIEFFECT by incorporating fenestrations to allow for fluid movement through the tissue. A hallmark of our success has been, and will continue to be, a commitment to market-driven innovation.”
EPIXPRESS expands MIMEDX’s PURION®-processed placental allograft offering aimed at helping clinicians treat acute and chronic, hard-to-heal wounds. Like EPIEFFECT, EPIXPRESS is a lyophilized product, and features a thick, tri-layer configuration. Additionally, EPIXPRESS adds fenestrations to the sheet configurations to help with fluid movement. EPIXPRESS can be used on a wide range of common conditions, such as diabetic foot ulcers (“DFUs”) and venous leg ulcers (“VLUs”), and other wound types, including those where the need exists to secure the graft in place with sutures. In addition, its product attributes and handling characteristics make it a preferable treatment option for deep or tunneling wounds.
About EPIXPRESS
EPIXPRESS is a lyophilized human placental-based allograft that includes the amnion layer, intermediate layer, and chorion layer. EPIXPRESS is intended for use as a barrier to provide a protective environment in acute and chronic wounds. The product provides a biocompatible human Extracellular Matrix (ECM) and contains 300+ regulatory proteins. Additionally, like MIMEDX’s other Wound products, including EPIFIX®, EPICORD®, EPIEFFECT®, CELERA™ and EMERGE™, EPIXPRESS is listed on the Medicare Part B Average Sales Price File. To learn more, please visit https://www.mimedx.com/EPIXPRESS/.
About MIMEDX
MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com.
Contact:
Matt Notarianni
Investor Relations
470-304-7291
mnotarianni@mimedx.com
FAQ
What is EPIXPRESS from MiMedx (MDXG) announced October 6, 2025?
Which wound types can EPIXPRESS treat for MDXG investors and clinicians?
How does EPIXPRESS differ from EPIEFFECT according to MiMedx (MDXG)?
When did MiMedx (MDXG) launch EPIXPRESS?
Is EPIXPRESS described as an existing technology or organically developed product for MDXG?
What handling or clinical advantages does EPIXPRESS offer according to MiMedx (MDXG)?
